We have extensive experience and capabilities in all aspects of commercialising products in European markets. When combined with our unwavering commitment to placing the patient at the heart of what we do, it means we can consistently launch and deliver rare and ultra rare disease medication across Europe.
Here is a quick overview of our capabilities below.
We are fully licensed and hold all the relevant EMA, GDP and MHRA licenses. It means we have a fully licensed medical warehouse for all temperature regimes and can move pre-licensed products.
We’ll take ownership of your product to improve your cash flow and manage all of the risk, while offering you a transparent supply chain process.
We’re on-hand to provide support from order to dispensing point delivery across every language in Europe & beyond.
In the last year we’ve taken 1.1 million orders, made 1.2 million deliveries, along 48,000 delivery routes, across 25 countries – all temperature controlled with continuous tracking from start to finish.
We operate in a highly regulated environment where safety and governance are key. That’s why we’ve put in place many cross-functional boards and committees to ensure patient safety and the highest levels of governance.
Approximately 50% of our staff are clinically qualified and each hub has its own GDP Responsible Person. Our breadth of nursing expertise covers administration and training of biologics through to second cycle therapy.
As your partner, we can support you from the very first clinical trials through to support for your patients and outcome monitoring. Our services are designed specifically for the future challenges of gene therapy.
